Environmental factors that play a role in the pathogenesis of bladder cancer have been characterized for many years. Current research into the pathophysiology of bladder cancers has begun to focus more on genetic alterations that are important in tumorigenesis. Low penetrance polymorphisms, such as N-acetyl transferase 2, glutathione S-transferase, and others have also shown to increase the risk of bladder cancer by altering the processing of environmental toxins. 
Introduction
In 2017, it is estimated that bladder cancer will compose 5% of all new cancer diagnoses at around 79,030 new cases [1] . Additionally, an anticipated 16,870 deaths (3% of all projected cancer deaths) will be due to bladder cancer [1] . A number of factors have been identified that contribute to the development of bladder cancer. Environmental factors, such as cigarette smoking and exposure to aromatic amines have been identified as the major contributors to increased bladder cancer risk [2] [3] [4] . However, the genetic and inheritable components of bladder cancer remain more of a mystery. Identification of Mendelian inheritance patterns in bladder cancer has been difficult due to a limited number of familial cases to explore [5] . New case reports and case studies have slowly become available, as well as follow up on families with multiple effected members. Large case studies are also limited with few new studies available.
The most information regarding the heritability of bladder cancers seems to arise from the new research into Lynch syndrome and low penetrance polymorphisms [6] [7] [8] .
The association of Lynch syndrome with urothelial cancers is relatively new. Urothelial cancers were only recently included in the criteria that assist in the diagnosis of Lynch syndrome [8] . The malignancies classically associated with Lynch syndrome are colorectal cancer and, to a degree, endometrial cancer [9] [10] [11] [12] [13] [14] . These tumors have seen much more extensive study in their relation to Lynch syndrome than urothelial and other cancers. Moreover, while the association between Lynch syndrome and upper tract urothelial cancers is apparent, the direct relationship between Lynch syndrome and bladder cancers is less well understood. Increases in bladder cancer in patients with Lynch syndrome may be the result of downstream seeding from primary upper tract cancers, and may not represent primary bladder cancers [8] . More research is necessary in this area to truly delineate the relationship. 4 In addition to Lynch syndrome, research is also active regarding low penetrance polymorphisms and their relation to bladder cancer. The most prolific polymorphisms include Nacetyl transferase and glutathione S-transferase. The presence of these polymorphisms only slightly increases the individual risk of bladder cancer, but they are prevalent in certain populations. The role these polymorphisms play in familial clustering of bladder cancers is still poorly understood. However, multiple polymorphisms coupled with consistent environmental exposure may explain families with multiple generations affected by bladder cancer [7] .
Case based evidence for inherited variants of bladder cancer
The first case study to mention a familial linked bladder cancer was published in the late 1950's. In this paper, Thelen and Schaebule presented monozygotic twins with transitional cell papillomas of the bladder [15] . Since that time, several additional case studies have presented families with multiple members affected by bladder cancers. A paper published in 1967 by
Fraumeni and Thomas reported a father and three of his sons with bladder transitional cell carcinoma [16] . Blattner et al. published follow up for this family in 1983 with additional follow up by Mueller et al. in 2008[7, 17] . At that time, the niece of the proband had also been diagnosed with bladder cancer. All affected family members reported an extensive smoking history, but had no other identifiable environmental risk factors. Studies for the more common variable penetrance polymorphisms were also performed, but all affected family members were negative for the genes associated with higher bladder cancer risk.
Mcullough et al. also reported a family with six affected family members in only two generations. This family also had numerous other cancers [18] . In their paper from 2008, Mueller et al. also summarized 16 case studies involving 32 families with transitional cell 5 carcinoma. Important factors to note in these cases are exposures to known environmental risk factors, mainly smoking and occupation exposure to aromatic amines. For 40 of the 86 affected individuals, smoking history was unavailable. In the remaining 46 patients, 33 had a positive smoking history. In this conglomerate of cases, smoking history was reported in at least one family member in all of the cases [7] . A more concise version of the table presented in that article is shown in Table 1 [7, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , with the addition of some more recent case studies.
Studies of more recent cases on familial clustering of bladder cancers include Ilic et al., where they describe a mother and son with bladder transitional cell carcinoma [27] . In addition, Brown et al. introduced two families with three cases of bladder transitional cell carcinoma each [28] .
Deciphering the underlying predisposing factors in these families remains a challenge.
Some patients had clear risk factors with smoking histories or occupational exposure to carcinogens. Others have no discernable risk factors, even when tested for cancer-predisposing polymorphisms. The paucity of available cases in this regard limits the information that can be ascertained from these case studies. Ultimately, more cases with are required to reach a more definitive conclusion.
Population based evidence for inherited variants of bladder cancer
Kramer et al. conducted a cross-sectional study in 1991 on 319 men with bladder cancer and another 319 neighborhood controls. In this study, an investigation was made into the relatives of the selected participants. The study looked at 1619 relatives of the men with bladder cancer and identified 14 family members with bladder cancer. Only seven effected family members were identified out of the 1773 members of the control group [29] . Kiemeney et al. 6 reviewed the families of 190 bladder cancer patients in Iceland and found family members with urinary tract transitional cell carcinoma in 41 of the families. Of interest in this study is that 2 nd and 3 rd degree relatives were more commonly affected [30] . A large case-control study in the Netherlands looked at 8014 family members of patients with transitional cell carcinoma and 5673 control relatives. One hundred and one relatives with urinary tract cancers were found in the family members of patients with urinary tract transitional cell carcinoma, whereas only 38 family members were affected among controls [31] . A study from Spain of 1158 cases reported increased risk for developing bladder cancer in those with a positive family history. This was stronger among slow acetylators, but not to a degree that was statistically significant [32] . 
Bladder cancer susceptibility genes
Some of the most well known risk factors for bladder cancer are environmental toxins.
Cigarette smoke and occupational exposure to aromatic amines have been well studied and their 7 contribution is clear [2] . Less well understood, however, is how genetic differences between individuals and their ability to process these toxins effect the development of bladder cancer.
Environmental toxins are processed by a number of different enzymes. Many polymorphisms have been identified that may increase the risk for developing bladder cancer [7] .
N-acetyl transferase 2 is one of the most prominent polymorphisms in the literature.
This polymorphism is extremely prevalent, found in approximately 50% of Caucasians. The odds ratio of the development of bladder cancer in patients with this polymorphism is 1.4 (95% CI 1.2-1.6) [7] . The protein product of this gene is responsible for detoxifying amines. with the null phenotype for this gene find themselves at greater risk for developing bladder cancer [7, 37] .
Some studies have estimated that 31% of bladder cancer in Caucasians may be due to deficiency of glutathione S-transferase or N-acetyl transferase 2. Additionally, many other gene variations have been studied and proposed as increasing the risk of familial bladder cancer [37] .
These genes require more study, but give us more insight into the development of bladder cancer.
Lynch Syndrome

Epidemiology
Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer is the most common cause of hereditary colorectal and endometrial cancers, accounting for approximately 1-3% of all colorectal cancers and 2-5% of all endometrial cancers [8] . Lynch syndrome is classically associated with increased risk of colorectal cancer, but also increases the risk of several other cancers ( Table 2) [8, 38, 39] . In women, endometrial cancer may actually be the sentinel malignancy [11] . A subset of Lynch syndrome, Muir-Torre syndrome, can also result in skin and sebaceous gland malignancies [40] . Lynch syndrome patients are additionally at increased risk for ovarian, urinary tract, stomach, small bowel, hepatobiliary, and central nervous system neoplasms [8] . The association of Lynch syndrome with these neoplasms is still growing due to limitations of early studies of Lynch syndrome, including small sample size, lack of disease confirmation, and limited or no availability of genetic testing. There is also equivocal evidence that malignancies of the prostate, testis, kidney, and adrenal gland may be slightly increased in Lynch syndrome patients. The susceptibility in Lynch syndrome to these particular 9 neoplasms is not as frequently reported and they may develop through pathways other than MSI [8] .
The risk of urothelial tract cancer in Lynch syndrome has been reported to increase by up to 28% [8, 41] . Research shows these urothelial tract cancers to include renal pelvis and ureter tumors (Figure 1) . Bladder cancers noted in cases of Lynch syndrome could be due to implantation of tumor cells from upstream into the bladder mucosa. The true risk may be even higher, with some urothelial cancers suspected to be misclassified as sporadic [8] .
Research has shown that sporadic colorectal cancers have different characteristics than colorectal cancers associated with Lynch syndrome [8] . Lynch syndrome associated cancers present at a younger mean age, which are usually right sided, and more likely multifocal.
Additionally, colon polyps in Lynch syndrome patients develop at a younger age, are smaller, and are more likely to be villous polyps. Differences between sporadic and Lynch syndrome associated urothelial cancers are also seen with Lynch syndrome patients more likely to develop urothelial cancers at a younger age (an average of 8 years younger according to one study), though one study showed no association with early bladder cancers and MSI. Additionally, there appears to be a slight female predominance and some studies suggest higher incidence of bilateral involvement of the upper urothelial tract [8] . One study suggested an association between inverted growth pattern and MSI and Lynch syndrome[42].
Prognosis and response to treatment also varies in sporadic versus Lynch syndrome associated colorectal cancers, and it has been postulated that the same may be true for urothelial cancers. Patients with Lynch syndrome associated colorectal cancers appear to have superior overall survival [8] . More research is still required to evaluate the differences between sporadic and Lynch syndrome associated urothelial cancers. 10 
Genetics
Lynch syndrome is an autosomal dominant genetic disease caused by mutations in mismatch repair (MMR) genes. Four mismatch repair genes can be mutated in Lynch syndrome, and a mutation in one of these genes predisposes to several different malignancies. Additionally, a mutation in the MSH2 gene seems to confer a higher risk for urothelial cancer than mutations in the other MMR genes. The increase in urothelial cancers is predominantly within the renal pelvis and ureters. Some studies have shown an increased risk for bladder cancer as well, but this increased risk may be due to seeding of the bladder from primary tumors that are upstream [8] .
Diagnosis
When thinking of Lynch syndrome, clinicians classically associate this disease with GI malignances, thus a disease specific to gastroenterologists. However, urologists also need to be aware of Lynch syndrome when patients present with primary bladder cancers. Urologists play Initial identification of Lynch syndrome in patients who present with urothelial cancers is similar to algorithms used with colorectal cancers [8] . Screening for patients with colon cancer 12 usually takes the form of MSI testing in patients with colorectal cancer who are younger than 50 years old. This form of testing is generally cost effective while also detecting most of the patients with Lynch syndrome. Prediction models can also be helpful [13, 14, 43] .
Testing for MSI in urothelial tumors should be focused on those patients for whom there is high clinical suspicion (Figure 2) . The clinical history is paramount in identifying those patients who would benefit most from testing. An extensive family pedigree is a major aid and should be collected on all patients. The Bethesda Guidelines and the Amsterdam II criterion are a useful tool for clinicians. The Amsterdam II criteria, however, are somewhat strict and may fail to identify some patients with Lynch syndrome. The sensitivity of the criteria have been reported to be approximately 72%, and studies using more broad criteria for testing have been able to identify additional Lynch syndrome patients that were missed on screening with the Amsterdam II criteria. Some international guidelines use upper tract urothelial cancer and age less than 60 as a trigger for genetic testing [8, 43] .
Patients who present at a young age (<60 years), with a family history of urothelial, 
Screening for urothelial cancers in patients with diagnosed Lynch syndrome
Patients with Lynch syndrome require a number of distinct considerations in regard to screening for Lynch syndrome associated cancers. Colonoscopies in these patients should be performed earlier and more frequently. The appropriate frequency and age of first colonoscopy can vary depending on particular gene effected within the family, as well as the age of first colorectal cancer diagnosis in the family [14] . Additionally, female Lynch syndrome patients should be advised to consider early hysterectomy to prevent endometrial cancers [11] .
Patients with diagnosed Lynch syndrome require special consideration for early identification of urothelial tract cancers. There is still no widely agreed upon method for screening these patients. Urinalysis and urine cytology remain the default screening method for patients with Lynch syndrome. These methods are fairly cheap and noninvasive which make 14 them an easy to perform screening test. Urine cytology, however, has a low sensitivity of approximately 29%, despite its high specificity for high grade lesions. This means that many patients with low-grade urinary tract cancers can easily be overlooked with this testing.
Therefore, urine cytology should not be used alone for screening Lynch syndrome patients for urothelial cancers. Other suggested methods have included renal ultrasound, urine dipstick, and NMP-22 testing. Patients with a previously diagnosed urothelial tract cancer or the MSH-2 mutation are considered to be at higher risk of tumor formation and vigilance in these patients is prudent [8] .
Hematuria identified on urinalysis can be a concerning feature and should be investigated further. Gross hematuria requires the default urological evaluation, including cystoscopy and biopsy. Microhematuria as a tool has low sensitivity for the evaluation of recurrent upper tract cancers, with a sensitivity of approximately 37.5%. Microhematuria is also relatively common in the general population, with no history of urothelial cancers [8] . One study revealed 41% of the general population to have a urinalysis with microhematuria [44] . Microhematuria should trigger further evaluation with greater than 3 red blood cells per high power field.
Routine imaging studies in patients with Lynch syndrome are common, but also pose risk with increased radiation exposure. Patients with a previously diagnosed malignancy can expect yearly CT imaging. Patients at higher risk, those with previous upper urothelial tract cancers or PMS2 mutations, may benefit from routine CT urograms [8] .
More definitive methods for identifying early urothelial tract tumors are not without their risks. Cystoscopy is minimally invasive, visualization of the ureters and renal pelvis requires more risk to the patient. This may include radiation exposure and exposure to anaesthetic [45] . 15 The association of Lynch syndrome with urothelial cancers is not as old as the association with colorectal and other cancers. It was not until the Amsterdam Criteria II revision in 1999 (Table 3) [34] that non-colonic Lynch syndrome cancers began to be truly appreciated.
Therefore, more research is required to hone our knowledge regarding urothelial cancers and Lynch syndrome [8] .
Patients 
Conclusions
The medical literature to this point does not provide irrefutable evidence for a true
Mendelian pattern bladder cancer. Since the first case report by Thelen and Schaebule, many more cases have been reported which portray many families with multiple members affected by bladder cancer. Additional risk factors are present within many of these families, making it more difficult to elucidate the true role of inheritance. With these environmental exposures in common to explain the familial clustering, a true Mendelian cause becomes less likely.
Population based studies using large patient databases have also given us some information. All of these studies have revealed that relatives of patients with bladder cancer are more likely to develop bladder cancer themselves when compared to the general population. Part of this increased risk could be attributed to shared environmental factors, as in some of the individual case studies. Close relatives are likely to share important history characteristics, such as 16 smoking and occupational exposures to aromatic amines. In addition, the case literature is limited in that most of these cases follow only a couple of generations. Few multigenerational cases have been reported. Not all of these population based studies may have the important historical data available, but even so, it seems unlikely that all of the familial clustering can be attributed to environmental risk factors. This is where the genetic polymorphisms may play a role. Many polymorphisms have come to light that seem to increase the risk of bladder cancer.
The NAT2 and glutathione transferase genes seem to be some of the more well studied genes, but many more have been characterized as increasing the risk of bladder cancer. Even more so, other cancer predisposition syndromes such as Lynch syndrome have shown that they can lead to increased incidence of bladder cancer. These add an additional level of difficulty when trying to evaluate families for potential Mendelian patterns of inheritance. At this point, more study is required to more clearly elucidate the myriad factors involved in the development of bladder cancer.
Lynch syndrome is one important factor to consider in inherited urothelial tumors.
Though these types of tumors are less well studied in Lynch syndrome, the current research clearly shows the increased risk of urothelial tumors in this syndrome. Screening of patients with known Lynch syndrome is also important to evaluate for development of new primary tumors.
Future Perspective
The coming years will undoubtedly bring us a greater understanding of the genetics of bladder cancer. Study into these genetic alterations is becoming a topic of increasing interest 17 with many new polymorphisms being identified, as well as our understanding of urothelial cancers in Lynch syndrome being refined.
Much can be expected to surface about the association of Lynch syndrome and its role in urothelial cancers. Bladder, ureter, and renal pelvis cancers remained an underappreciated portion of the syndrome until the last couple of decades. This recognition has allowed an increasing number studies to shine light on these associations. In the future we will likely see further and more expansive studies to refine our understanding. The real association of Lynch syndrome and bladder cancer is still poorly understood, for example. We currently do not fully understand the actual risk of bladder cancer in Lynch syndrome. Increases in incidence may simply be due to downstream seeding from upper tract cancers. Further studies will no doubt illuminate this problem and provide us with more concrete answers.
Next generation sequencing is only just starting to blossom. Sequencing at this point is still expensive and the sequencing of multiple patients for study may not be practical in all cases.
As with most advances, the cost of next generation sequencing will likely decline rapidly over the coming years. As this process is made more efficient and cost effective we will see increased application in large scale studies in many areas, including bladder cancer and urothelial cancer research. Large scale application of this process will lead to the discovery of many additional genes in carcinogenesis in addition to improving our understanding in epidemiology for currently poorly understood alterations, such as many of the single nucleotide polymorphisms, which have limited evidence.
Additionally, screening for patients with Lynch syndrome may see changes in the coming years. Currently proposed screening methods involve measuring hematuria and the use of urine cytology with some providers using more costly and invasive measures such as cystoscopy or CT  Many of the effected family members in these case studies do share some environmental predispositions such as smoking and occupational exposures.
 The evidence is suggestive of additional genetic predispositions to bladder cancer, but no definitive conclusions can be made and further research is required.
Population based evidence for inherited variants of bladder cancer
 Patients with bladder cancer are more likely than the general population to have relatives who also have a history of bladder cancer.
Bladder cancer susceptibility genes
 N-acetyl transferase 2 polymorphism has been shown in some studies to increase the risk of bladder cancer.
 N-acetyl transferase 2 is found in approximately 50% of the Caucasian population.
 The slow acetylator phenotype for N-acetyl transferase 2 results in longer exposure times to environmental factors proven to cause bladder cancer.
 Glutathione S-transferase M1 is responsible for detoxifying polycyclic aromatic hydrocarbons.
 Inheritance of two null copies of the Glutathione S-transferase M1 gene result in a higher risk of bladder cancer. 
